1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Dyskinesia Global Clinical Trials Review, H1, 2016

Dyskinesia Global Clinical Trials Review, H1, 2016

  • March 2016
  • -
  • GlobalData
  • -
  • 228 pages

Dyskinesia Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Dyskinesia Global Clinical Trials Review, H1, 2016" provides an overview of Dyskinesia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyskinesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Dyskinesia Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Dyskinesia to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Dyskinesia to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Dyskinesia Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Dyskinesia 34
Dec 23, 2015: Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinsons Disease 34
Clinical Trial Profile Snapshots 36
Appendix 225
Abbreviations 225
Definitions 225
Research Methodology 226
Secondary Research 226
About GlobalData 227
Contact Us 227
Disclaimer 227
Source 228

List of Tables
Dyskinesia Therapeutics, Global, Clinical Trials by Region, 2016* 6
Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Dyskinesia Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
Dyskinesia Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 16
Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 20
Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22
Dyskinesia Therapeutics, Global, Clinical Trials by Phase, 2016* 23
Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 24
Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25
Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26
Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 28
Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 30
Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 32
Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 33

List of Figures
Dyskinesia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Dyskinesia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
Dyskinesia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 15
Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 19
Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 21
Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 22
Dyskinesia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 23
Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 24
Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 25
Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 26
Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 27
Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 28
Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29
Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31
Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 33
GlobalData Methodology 226

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

OpportunityAnalyzer: Hyperparathyroidism - Opportunity Analysis and Forecasts to 2025 Summary Hyperparathyroidism (HPT) is a common endocrinal disorder characterized by excessive plasma levels of parathyroid ...

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.